Combining Radiosurgery and Nivolumab in the Treatment of Brain Metastases
Status:
Active, not recruiting
Trial end date:
2022-06-01
Target enrollment:
Participant gender:
Summary
Stereotactic radiosurgery (SRS) is increasingly administered as the sole treatment of brain
metastases, in order to spare acute and long term side effects associated with whole brain
radiotherapy. Local control of SRS treated lesions is good, but patients tend to develop
additional brain metastases subsequently.
Nivolumab is a modulator of the immune system. Treatment with Nivolumab is associated with an
increase in local control and survival in patients with non-small cell lung cancer and clear
cell renal cell carcinoma. In the presence of Nivolumab, treatment of brain metastases with
SRS may trigger an immune reaction against cancer. Therefore, the combination of SRS with
Nivolumab may reduce the development of new brain metastases and improve patient survival.
The purpose of this study is to assess the effect of combining Nivolumab and SRS in
controlling cancer progression. SRS will be administered to patients while they are receiving
Nivolumab.